Literature DB >> 15297134

The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma.

Peter J Hoskin1, Amen Sibtain, Frances M Daley, Michele I Saunders, George D Wilson.   

Abstract

BACKGROUND AND
PURPOSE: Hypoxia and proliferation are important determinants of radiation responsiveness; prospective measures of these before radiotherapy may enable individualisation of treatment schedules. Immunohistochemical techniques offer a potential means of achieving this in routine biopsy material.
MATERIAL AND METHODS: Cellular hypoxia as measured by pimonidazole fixation and immunohistochemistry has been evaluated in a series of human bladder cancers with dual staining of sections for pimonidazole and either the vascular markers, CD31/34, or proliferation markers, Ki-67 or cyclin A. Twenty one tumour specimens were examined suitable for the double staining technique.
RESULTS: The median hypoxic fraction was 9% (range 0-38). Seven tumours did not stain for pimonidazole and 11 exhibited necrosis. The mean vascular density ranged from 16.7 to 160.6 vessels per mm2. The median hot spot count was 30 (range 16-43). There was a statistically significant increase in vessel density in hypoxic compared to oxic regions measured by both vessel density (P = 0.02) and hot spot count (P = 0.004). Proliferation indices decreased from oxic to hypoxic areas close to blood vessels.
CONCLUSIONS: We have demonstrated that bladder cancer exhibits a range of hypoxia, proliferation and vascular density which may be used to form the basis for patient selection for hypoxia modification, accelerated radiotherapy and vascular targeting agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297134     DOI: 10.1016/j.radonc.2004.03.017

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia.

Authors:  David J Carlson; Paul J Keall; Billy W Loo; Zhe J Chen; J Martin Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-12-22       Impact factor: 7.038

2.  The Relationship among Hypoxia, Proliferation, and Outcome in Patients with De Novo Glioblastoma: A Pilot Study.

Authors:  Sydney M Evans; Kevin W Jenkins; H Isaac Chen; W Timothy Jenkins; Kevin D Judy; Wei-Ting Hwang; Robert A Lustig; Alexander R Judkins; M Sean Grady; Stephen M Hahn; Cameron J Koch
Journal:  Transl Oncol       Date:  2010-06-01       Impact factor: 4.243

3.  Arterial Spin Labeling and Dynamic Susceptibility Contrast-enhanced MR Imaging for evaluation of arteriovenous shunting and tumor hypoxia in glioblastoma.

Authors:  S Ali Nabavizadeh; Hamed Akbari; Jeffrey B Ware; MacLean Nasrallah; Samantha Guiry; Stephen J Bagley; Arati Desai; Scott Levy; Whitney Sarchiapone; Timothy Prior; John Detre; Ronald L Wolf; Donald M O'Rourke; Steven Brem; Christos Davatzikos
Journal:  Sci Rep       Date:  2019-06-19       Impact factor: 4.379

Review 4.  The measurement and modification of hypoxia in colorectal cancer: overlooked but not forgotten.

Authors:  Teddy Fletcher; Alex J Thompson; Hutan Ashrafian; Ara Darzi
Journal:  Gastroenterol Rep (Oxf)       Date:  2022-08-25

5.  GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON.

Authors:  P J Hoskin; A Sibtain; F M Daley; G D Wilson
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.